The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to EPI-321 for the treatment of facioscapulohumeral muscular dystrophy (FSHD), the most common form of muscular dystrophy in adults. Read more here: ow.ly/g6p050Q88Qz
We are pleased to share that Epic Bio CEO Dr. Amber Salzman has been invited to present at the 2023 Stiefel Healthcare Conference. Read more here: ow.ly/hqtp50Q4QeO
@Epicbiotech partners with @KitePharma to extend the potential application of Epic’s platform for cancer treatment. Epic’s approach is promising for in vivo medicines and may enable next-generation cell therapies #epigenetics#CellTherapy#Cancer
This week at #ESGCT23, Epic Bio presented improvements to CasMINI, previously the smallest Cas protein known to work in human cells. We also shared progress of our epigenetic editing platform and EPI-321 for the treatment of FSHD. Read more here: ow.ly/gFV750Q1aSG
We are pleased to share that Epic Bio will present at the European Society of Gene and Cell Therapy conference October 24-27 in Brussels, Belgium. Read more here: ow.ly/pZup50PYFuR#epigenetics#FSHD#EpicBio
"🌍✨ Today is #WorldSightDay, a global initiative to raise awareness about vision impairment and blindness. Sight is a precious gift, and together, we can work towards a world where everyone can see the beauty around them. 👁️ #LoveYourEyes#EpicBio#Epigenetics
CEO, Amber Salzman, Ph.D., will present at the BMO Private Company Showcase on Thursday, October 12, 2023, in New York, NY. Institutional investors interested in meeting with management during the conference may contact their BMO representative. ow.ly/JPx750PTxF1
ICYMI: Epic Bio scientists recently published two papers, "Discovery and engineering of hypercompact epigenetic modulators for durable gene activation" and "Improving few-shot learning-based protein engineering with evolutionary sampling." Read more here: ow.ly/fZiI50PLGKC
We're honored to be named a #Fierce15 winner by @FierceBiotech! We’ve had a momentous year building our #EpigeneticEditing platform and advancing toward clinical entry early next year. And we’ve got much more in store! Follow for updates & read more here: bit.ly/3YPaOUR
We're proud to have presented 6 posters at @CSHL's Genome Engineering: #CRISPR Frontiers conference! The data show dramatic progress of our GEMS #EpigeneticEditing platform, incl. novel hypercompact Cas effectors we've developed. Read more: bit.ly/45bmmEb#cshlCRISPR23
ALT Epic Bio Presents New Data on Epigenetic Editing Platform at CRISPR Frontiers Conference
June 20 is World FSHD Day, and we want to take a moment to shine a light on our FSHD warriors; you inspire us with your resilience and strength. Your determination to face challenges head-on is truly commendable. #WorldFSHDDay#SupportFSHD#SolveFHSD#FSHDSociety
“Even though the story has never been tidy, and Black folks have had to march and fight for every inch of our freedom, our story is nonetheless one of progress.” —Michelle Obama